Novirio Pharmaceuticals

Novirio is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Novirio's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus. A registration statement relating to these securities has... been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the preliminary prospectus relating to the offering may be obtained by contacting the prospectus departments of Goldman Sachs & Co. [85 Broad Street, Attn: Don Hansen, Floor 15, New York, NY 10004] or Banc of America Securities LLC [c/o Jeff Liubicich, CA5-801-06-29, 600 Montgomery Street, 6th Floor, San Francisco, CA 94111].Read More